ReviewEuropean radiology2018
Implementing diffusion-weighted MRI for body imaging in prospective multicentre trials: current considerations and future perspectives.
Review in European radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Neuroimaging in Randomized, Multi-Center Clinical Trials of Endovascular Treatment for Acute Ischemic Stroke: A Systematic Review.Korean journal of radiology · 2020Pooled it
- Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer.Nature communications · 2020Trial
- Differentiating lymph node status in malignant melanoma: the role of apparent diffusion coefficient ratio in diffusion-weighted MRI - a prospective diagnostic study.BMC medical imaging · 2026Article
- Giving the prostate the boost it needs: Spiral diffusion MRI using a high-performance whole-body gradient system for high b-values at short echo times.Magnetic resonance in medicine · 2025Article
- The QIBA Profile for Diffusion-Weighted MRI: Apparent Diffusion Coefficient as a Quantitative Imaging Biomarker.Radiology · 2024Review
- A multicenter study of cervical cancer using quantitative diffusion-weighted imaging.Acta radiologica (Stockholm, Sweden : 1987) · 2024Article
- Differentiating inflammatory and malignant pulmonary lesions on 3T lung MRI with radiomics of apparent diffusion coefficient maps and T2w derived radiomic feature maps.Journal of thoracic disease · 2024Article
- The development process of 'fit-for-purpose' imaging biomarkers to characterize the tumor microenvironment.Frontiers in medicine · 2024Review
- Changes in serial multiparametric MRI and FDG-PET/CT functional imaging during radiation therapy can predict treatment response in patients with head and neck cancer.European radiology · 2023Article
- Repeatability of quantitative individual lesion and total disease multiparametric whole-body MRI measurements in prostate cancer bone metastases.The British journal of radiology · 2023Article
- The role of clinical imaging in oncology drug development: progress and new challenges.The British journal of radiology · 2023Review
- Microstructural Changes in the Spinothalamic Tract of CPSS Patients: Preliminary Results from a Single-Center Diffusion-Weighted Magnetic Resonance Imaging Study.Brain sciences · 2023Article
- A whole-body diffusion MRI normal atlas: development, evaluation and initial use.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- Article
- Evaluation of Apparent Diffusion Coefficient Repeatability and Reproducibility for Preclinical MRIs Using Standardized Procedures and a Diffusion-Weighted Imaging Phantom.Tomography (Ann Arbor, Mich.) · 2023Article
- Standardised lesion segmentation for imaging biomarker quantitation: a consensus recommendation from ESR and EORTC.Insights into imaging · 2022Article
- Quantitative imaging of uterine cancers with diffusion-weighted MRI and 18-fluorodeoxyglucose PET/CT.Abdominal radiology (New York) · 2022Review
- Diffusion-Weighted Magnetic Resonance Imaging in Ovarian Cancer: Exploiting Strengths and Understanding Limitations.Journal of clinical medicine · 2022Review
- Long-Term Stability of Gradient Characteristics Warrants Model-Based Correction of Diffusion Weighting Bias.Tomography (Ann Arbor, Mich.) · 2022Article
- Semi-automatic quantitative analysis of the pelvic bony structures on apparent diffusion coefficient maps based on deep learning: establishment of reference ranges.Quantitative imaging in medicine and surgery · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 10 institutions in 5 countries.
Funding
Abstract
For body imaging, diffusion-weighted MRI may be used for tumour detection, staging, prognostic information, assessing response and follow-up. Disease detection and staging involve qualitative, subjective assessment of images, whereas for prognosis, progression or response, quantitative evaluation of the apparent diffusion coefficient (ADC) is required. Validation and qualification of ADC in multicentre trials involves examination of i) technical performance to determine biomarker bias and reproducibility and ii) biological performance to interrogate a specific aspect of biology or to forecast outcome. Unfortunately, the variety of acquisition and analysis methodologies employed at different centres make ADC values non-comparable between them. This invalidates implementation in multicentre trials and limits utility of ADC as a biomarker. This article reviews the factors contributing to ADC variability in terms of data acquisition and analysis. Hardware and software considerations are discussed when implementing standardised protocols across multi-vendor platforms together with methods for quality assurance and quality control. Processes of data collection, archiving, curation, analysis, central reading and handling incidental findings are considered in the conduct of multicentre trials. Data protection and good clinical practice are essential prerequisites. Developing international consensus of procedures is critical to successful validation if ADC is to become a useful biomarker in oncology. KEY POINTS: • Standardised acquisition/analysis allows quantification of imaging biomarkers in multicentre trials. • Establishing "precision" of the measurement in the multicentre context is essential. • A repository with traceable data of known provenance promotes further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.